Hepatitis B immunoglobulin (HBIG) withdrawal from combination lamivudine (LAM)/HBIG prophylaxis in liver transplant recipients.

Trial Profile

Hepatitis B immunoglobulin (HBIG) withdrawal from combination lamivudine (LAM)/HBIG prophylaxis in liver transplant recipients.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Lamivudine (Primary) ; Adefovir dipivoxil; Hepatitis B immune globulin
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Oct 2011 Additional lead trial centre identified as reported by ISRCTN: Current Controlled Trials record.
    • 02 Oct 2011 Status changed from active, no longer recruiting to completed ISRCTN: Current Controlled Trials record.
    • 22 Jul 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top